42 results
6-K
EX-99.1
LSB
LakeShore Biopharma Co., Ltd
8 Oct 24
Report of Foreign Private Issuer
8:59am
, the progress and results of all clinical trials, LakeShore Biopharma’s ability to source and retain talent, and the cash position of LakeShore
6-K
EX-99.1
LSB
LakeShore Biopharma Co., Ltd
27 Sep 24
LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation
7:15am
ability to source and retain talent, and the cash position of LakeShore Biopharma. Forward-looking statements may be identified by the use of words
6-K
EX-99.1
LSB
LakeShore Biopharma Co., Ltd
10 Sep 24
Report of Foreign Private Issuer
8:15am
progress of all product candidates, the progress and results of all clinical trials, LakeShore Biopharma’s ability to source and retain talent
6-K
EX-99.1
LSB
LakeShore Biopharma Co., Ltd
15 Aug 24
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024
8:40am
and results of all clinical trials, LakeShore Biopharma’s ability to source and retain talent, and the cash position of LakeShore Biopharma. Forward
6-K
EX-99.1
wboyvudvdaj48m
5 Jul 24
Report of Foreign Private Issuer
7:15am
6-K
yb1ia2eot na1gb
10 Jun 24
Report of Foreign Private Issuer
7:01am
424B3
qxn4zj12ohgq hz
8 May 24
Prospectus supplement
8:32am
6-K
EX-99.1
cb5kl3k38u f6bo8iq
7 May 24
Report of Foreign Private Issuer
4:30pm
6-K
EX-99.1
xzq8 mydx
29 Apr 24
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
8:15am
6-K
EX-99.1
snx9gqm11jc 31alf549
19 Apr 24
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
8:03am
6-K
EX-99.1
iv6 o4ls8
18 Apr 24
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
8:15am
6-K
EX-99.1
8ap63e8z w50uao
9 Apr 24
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine
8:20am
6-K
EX-99.1
a09sivo8s5296cee7qm
3 Apr 24
YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility
8:10am
6-K
EX-99.1
53058kyr6gc60
16 Feb 24
YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting
8:25pm
6-K
EX-99.1
pv1z9qae anh9i963
14 Feb 24
Report of Foreign Private Issuer
8:05am
6-K
EX-99.1
iq6 4atxrt7dwe
14 Feb 24
YS Biopharma Announces Appointment of New Directors
8:01am
6-K
EX-99.1
3z6jl
9 Feb 24
YS Biopharma Announces US$40 Million Private Placement Financing
7:10am
POS AM
0cyukhegp6v9inhgd sa
23 Jan 24
Prospectus update (post-effective amendment)
4:18pm
6-K
EX-99.1
gmodugio0w 8r
22 Jan 24
YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024
5:10pm